Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01526096 · ClinicalTrials.gov registry record · Phase 1

Stem Cell Transplantation for Patients With Multiple Myeloma

A Phase 1 study of Myeloma, sponsored by University of Chicago.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT01526096 is a Phase 1 study of Myeloma that has completed, run by University of Chicago. The registered enrollment target is 30 participants, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01526096, a Phase 1 study of Myeloma, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).

Conditions Studied

Myeloma

Interventions

  • DRUG Melphalan
  • DRUG G-CSF
  • PROCEDURE Apheresis
  • DRUG Plerixafor
  • PROCEDURE Stem cell re-infusion

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-07-12
Est. Completion 2024-08-28
Phase Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01526096

The ClinicalTrials.gov registry entry for NCT01526096 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (70% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.

NCT01526096 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT01526096 about?

NCT01526096 is a clinical study titled "Stem Cell Transplantation for Patients With Multiple Myeloma". The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).

What is the current status of trial NCT01526096?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-07-12. Estimated completion is 2024-08-28.

What conditions does trial NCT01526096 study?

This clinical trial studies the following conditions: Myeloma.

What interventions are being tested in trial NCT01526096?

The interventions under investigation include: Melphalan (DRUG), G-CSF (DRUG), Apheresis (PROCEDURE), Plerixafor (DRUG), Stem cell re-infusion (PROCEDURE).

Who is sponsoring clinical trial NCT01526096?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01526096 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myeloma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.